<unk>  is an antineoplastic agent that is FDA approved for the treatment of patients with metastatic and/or progressive carcinoma of the prostate.   Common adverse reactions include edema, breast tenderness, diarrhea, gastrointestinal irritation, nausea, leg cramp and dyspnea.
Estramustine
Bendamustine
Fotemustine
Lomustine
Prednimustine
Idoxuridine
Floxuridine
Carmustine 